SCHEMBL97944

SCHEMBL97944

CC(C)(Cc1ccc([N+](=O)[O-])cc1)[N+](=O)[O-]

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.52
TSHR P16473 1/20 0.48
IDO1 P14902 2/20 0.47
ALDH1A1 P00352 3/20 0.47
ACHE P22303 2/20 0.47
HSD17B10 Q99714 1/20 0.47
KDM4E B2RXH2 1/20 0.46
AKR1C3 P42330 1/20 0.46
CYP2C19 P33261 4/20 0.46
POLB P06746 1/20 0.46
HSD11B1 P28845 1/20 0.44
BCHE P06276 1/20 0.44
CYP1A2 P05177 3/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
CYP2C9 P11712 1/20 0.43
KCNJ1 P48048 1/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11758080 0.92 HSD11B1 (0.46) LOXL2TSHRIDO1ALDH1A1ACHE
SCHEMBL1627332 0.85 TSHR (0.53) LOXL2TSHRIDO1ALDH1A1ACHE
SCHEMBL75530 0.84 LOXL2 (0.55) LOXL2TSHRIDO1ALDH1A1ACHE
SCHEMBL5527114 0.82 ACHE (0.43) TSHRIDO1ALDH1A1ACHEHSD17B10
SCHEMBL99082 0.82 FDPS (0.44) LOXL2TSHRALDH1A1CYP2C9
SCHEMBL11757972 0.81 TSHR (0.55) LOXL2TSHRIDO1ALDH1A1ACHE
SCHEMBL5830105 0.81 ESR1 (0.55) TSHRALDH1A1KDM4E
SCHEMBL10305277 0.81 MAPT (0.37) ALDH1A1
SCHEMBL7107843 0.81 LOXL2 (0.52) LOXL2TSHRIDO1ALDH1A1ACHE
SCHEMBL776520 0.81 LOXL2 (0.57) LOXL2TSHRIDO1ALDH1A1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9072734-B2 Quaternary ammonium salt compounds TEIJIN PHARMA LIMITED (JP) 2015-07-07 US disclosed
US-8299123-B2 CCR10 antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-30 US disclosed
US-8299123-B2 CCR10 antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-30 US disclosed
EP-2215065-B1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2012-07-11 EP disclosed
EP-2426121-A1 QUATERNARY AMMONIUM SALT COMPOUND Teijin Pharma Limited (JP) 2012-03-07 EP disclosed
US-20120046467-A1 QUATERNARY AMMONIUM SALT COMPOUNDS TEIJIN PHARMA LIMITED (JP) 2012-02-23 US disclosed
US-20110039851-A1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-17 US disclosed
US-20110039851-A1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-17 US disclosed
WO-2009052078-A1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-23 WO disclosed
US-4024185-A REDUCTION OF AROMATIC DINITRO COMPOUNDS ALLIED CHEMICAL CORPORATION (US) 1977-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046467-A1 QUATERNARY AMMONIUM SALT COMPOUNDS ADRB2, AGTR2, ADRB3 LOXL2 4700/4885TSHR 150/4885IDO1 3275/4885
US-20110039851-A1 CCR10 ANTAGONISTS CCR10, CCR1, CCR4 LOXL2 2382/4885TSHR 1523/4885IDO1 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.